EDIT
Editas Medicine, Inc.
Nasdaq: EDIT · Cambridge, MA · Healthcare
$3.30-0.27 (-7.56%)Closed
Market Cap$323.0M
Cash$146.6Mmost recent
Runway9 mo$47.8M Q burn
P/E (TTM)—EPS $-1.80
52-Wk Range$1.33 – $4.15
Avg Volume2.1M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$3.30-41.1%
Pipeline

Drug candidates sponsored by Editas Medicine · ClinicalTrials.gov

4 drugs · 5 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 1EDIT-101
Leber Congenital Amaurosis 10+6 more
Unknown
2025-05-23past
1
Phase 1EDIT-301
Sickle Cell Disease+4 more
Active, not recruiting
2025-09past
2
N/AUnnamed
Blindness+7 more
Completed
2022-05-06past
1
N/AUnnamed
Sickle Cell Disease+2 more
Enrolling
2040-08
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.